You are here

reimbursement

What Will Keep Medtech up at Night in 2019?

What Will Keep Medtech up at Night in 2019?

Medical Devices and Diagnostics Industry

Flag link:

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

Hospital docs weigh in on CAR-T reimbursement: 'It's very complicated'

BioSpace

Flag link:

CMS rule cuts reimbursement for new Part B drugs

CMS rule cuts reimbursement for new Part B drugs

BioCentury

Medicare Part B

physician-administered drugs

Flag link:

Reimbursement lags cancer drug approvals, but some European countries wait longer

Reimbursement lags cancer drug approvals, but some European countries wait longer

Biopharma Dive

Flag link:

Better U.S. Patient Access To Cancer Drugs Comes At A Price

Better U.S. Patient Access To Cancer Drugs Comes At A Price

Forbes

Flag link:

Medicare sets outpatient rate for Yescarta reimbursement

Medicare sets outpatient rate for Yescarta reimbursement

Reuters

Gilead Sciences

Flag link:

Medical device reimbursement: How it’s a brave new world

Medical device reimbursement: How it’s a brave new world

Medical Design and Outsourcing

Flag link:

Reimbursement Trends for Medical Devices in Japan

Reimbursement Trends for Medical Devices in Japan

Medical Devices and Diagnostics Industry

Flag link:

Medical Device Reimbursement in the US

Medical Device Reimbursement in the US

RAPS.org

Flag link:

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Drug Channels

Flag link:

Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?

Can Novartis' Kisqali beat Pfizer's market-leading Ibrance to reimbursement in England?

Fierce Pharma

Flag link:

Why regional reimbursement strategies could be right for medtech

Why regional reimbursement strategies could be right for medtech

Medical Design and Outsourcing

Flag link:

5 hurdles facing biosimilar developers

5 hurdles facing biosimilar developers

BioPharma Dive

drug development

drug manufacturing

Flag link:

Is Amgen still shooting blanks in its war with payers over Repatha reimbursement?

Is Amgen still shooting blanks in its war with payers over Repatha reimbursement?

Endpoints

Flag link:

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

Medical Marketing and Media

global launches

Flag link:

Are US reimbursement trends stifling medical device innovation?

Are US reimbursement trends stifling medical device innovation?

Mass Device

Flag link:

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Why Gathering Health Economic Data for Cancer Drugs is Now Essential

Medical Marketing and Media

health economics

Flag link:

A proposal for biosimilar reimbursement sparks outrage

A proposal for biosimilar reimbursement sparks outrage

Pharmalot

Flag link:

What's worrying pharma? Reimbursement, yes, but also M&A, global threats, and the economy

What's worrying pharma? Reimbursement, yes, but also M&A, global threats, and the economy

Fierce Pharma

Flag link:

Is this MannKind Corporation's Worst Nightmare?

Is this MannKind Corporation's Worst Nightmare?

Motley Fool

Flag link:

Pages